TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4096058
Drug: Haemodynamically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodynamically oriented differential therapy
Study: 30134289
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of nonintegrase inhibitor regimen
Study: 31594200
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Laser Therapy (HILT)
Study: 24356596
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes therapy (INT)
Study: 11773299
Drug: Paclitaxel-based adjuvant
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-based adjuvant chemotherapy
Study: 9649976
Drug: 10-day lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day lofexidine treatment
Study: 28268215
Drug: Buprenorphine oral
Normalized name: buprenorphine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine oral lyophilisate (bup-lyo)
Study: 28268215
Drug: Buprenorphine sublingual
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine sublingual tablets (bup-SL)
Study: 16765759
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg per day) plus aspirin (75-100 mg per day)
Study: 16765759
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy (for patients already receiving treatment at study entry)
Study: 16765759
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (for patients not on oral anticoagulation therapy at study entry)
Study: 11895463
Drug: Intracoronary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary treatment with oestrogen (group 2)
Study: 10102427
Drug: IFN‐alpha2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2a treatment
Study: 363490
Drug: Sulfonylurea or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea or insulin treatment
Study: 26067585
Drug: ABT-639 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-639 (100 mg twice daily)
Study: 7846309
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (2.0 g of soil/day)
Study: 2898400
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Imferon) administered by total dose infusion (TDI) at high dose
Study: 2898400
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Imferon) administered by total dose infusion (TDI) at low dose
Study: 31452382
Drug: Concomitant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatments for non-communicable diseases (NCD)
Study: 25225010
Drug: Palliative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy (three courses)
Study: 17059933
Drug: Papaverine injection
Normalized name: papaverine Injection
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine injection into the endothoracic fascia (Group 2)
Study: 17059933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of papaverine and carbon dioxide (Group 4)
Study: 9324179
Drug: Ketorolac by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac by bolus plus infusion (Ket I)
Study: 30413151
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg and 240 mg
Study: 24239201
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with calcium-channel blockers (CCBs)
Study: 24239201
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with CCB and atorvastatin 80 mg daily
Study: 24239201
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with CCB, statin, and proton pump inhibitor
Study: 12720542
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 800 mg/day
Study: 9142771
Drug: Extended-interval dosing
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-interval dosing of aminoglycosides
Study: 8457446
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (indomethacin)
Study: 8457446
Drug: Antihistamine (diphenhydramine)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (diphenhydramine)
Study: 12372721
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic chemotherapy
Study: 26162850
Drug: GVXN SD133
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVXN SD133 vaccine (2 μg with or without aluminium adjuvant)
Study: 26162850
Drug: GVXN SD133
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVXN SD133 vaccine (10 μg with or without aluminium adjuvant)
Study: 26162850
Drug: GVXN SD133
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVXN SD133 vaccine (2 μg or 10 μg)
Study: 16939923
Drug: remifentanil by
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil by TCI, propofol, and doxapram 0.6 mg/kg
Study: 8263313
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg venlafaxine
Study: 8263313
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg venlafaxine
Study: 1389931
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of venlafaxine
Study: 26828426
Drug: Progressive resistance-training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance-training intervention during radiation treatment
Study: 26828426
Drug: Progressive resistance-training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance-training intervention after radiation treatment
Study: 3322096
Drug: i.v. meptazinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. meptazinol 2 mg/kg
Study: 3322096
Drug: i.v. meptazinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. meptazinol 4 mg/kg
Study: 28196208
Drug: Single 8-Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 8-Gy radiotherapy dose for 1 or 2 bone metastases
Study: 12376849
Drug: Propofol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.6 mg/kg)
Study: 12376849
Drug: Ketamin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamin (0.6 mg/kg)
Study: 7488690
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet plus serotoninergic medication
Study: 21406694
Drug: Emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream
Study: 6257799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo preparation)
Study: 7128190
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral rinse
Study: 24970720
Drug: iCBT group‐therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT group‐therapy format (iCBT‐G)
Study: 16316359
Drug: Oral paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral paricalcitol
Study: 14963679
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment in cooperation with general practitioner (GP).
Study: 9602583
Drug: HBOC‐201 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 0.4 g kg‐1
Study: 9602583
Drug: HES 3
Normalized name: TELFA PAD NON-ADHES 3IN X 8IN NONSTERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 3 ml kg‐1
Study: 909027
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of povidone iodine on umbilical cord and normal intact skin
Study: 909027
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of povidone iodine on denuded skin
Study: 909027
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of povidone iodine
Study: 30978622
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy (PE) and Relaxation Training (RT)
Study: 1447501
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (50 mg/day)
Study: 20060078
Drug: teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide 20 mug/day by subcutaneous injection
Study: 20060078
Drug: alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 10 mg/day orally
Study: 6137468
Drug: Pindolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (beta-adrenergic antagonist)
Study: 22578834
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CTCA using FBP (protocol A)
Study: 16645456
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia
Study: 1595776
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus 10 mg glyburide before breakfast
Study: 1595776
Drug: Insulin-only group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only group
Study: 3967459
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg/day after 3 weeks)
Study: 3967459
Drug: Nadolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (240 mg/day after 3 weeks)
Study: 28195139
Drug: MDMA-HCl (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-HCl (100 mg p.o.)
Study: 21849603
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein (HP; 2.9 and 4.4 g protein/100 kcal)
Study: 21849603
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein (LP; 1.77 and 2.2 g protein/100 kcal)
Study: 20169858
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride orally disintegrating tablets with Indion‐204 as taste-masking agent
Study: 20169858
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride orally disintegrating tablets with Tulsion‐335 as taste-masking agent
Study: 20169858
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride orally disintegrating tablets with crospovidone as superdisintegrant
Study: 20169858
Drug: Optimum formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum formulation (F‐1) of levocetirizine dihydrochloride orally disintegrating tablets
Study: 17944177
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere 0.04%
Study: 14622808
Drug: Standardized exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized exercise therapy with functional electrical muscle stimulation
Study: 10647762
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (tinzaparin sodium)
Study: 28562168
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) monotherapy at an initial dose of 0.05-0.1 mg/kg/day
Study: 28562168
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) monotherapy
Study: 21543239
Drug: High-dose zonisamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zonisamide (6-8 mg/kg/day)
Study: 2982538
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with intra-arterial propranolol
Study: 2982538
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion with intra-arterial propranolol
Study: 2982538
Drug: Doxazosin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin infusion
Study: 8274583
Drug: Yohimbine infusion
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine infusion
Study: 27511182
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b (early treatment)
Study: 10743799
Drug: Placebo (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (delayed treatment)
Study: 24361086
Drug: Subcutaneous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous diclofenac HPbCD administered in gluteus
Study: 24361086
Drug: Subcutaneous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous diclofenac HPbCD administered in abdomen
Study: 20369059
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza vaccine (Sub/MF59)
Study: 17197592
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection
Study: 2207852
Drug: Sanguinaria toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguinaria toothpaste and oral rinse regimen
Study: 9769395
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: IFO 1.5 g/m2 i.v. as a 4 h infusion on days 1-5, Mesna 600 mg i.v. as push injection at 0 h, 4 h, 8 h on days 1-5, CDDP 20 mg i.v. as a 60 min infusion on days 1-5, repeated every 28 days for 3 cycles.
Study: 7918930
Drug: Flumecinol 600
Normalized name: Flumecinol
DrugBank: Flumecinol (DB18178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumecinol 600 mg once weekly for 3 weeks
Study: 7918930
Drug: Flumecinol 300
Normalized name: Flumecinol
DrugBank: Flumecinol (DB18178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumecinol 300 mg daily for 3 weeks
Study: 8460757
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with adrenaline (15 ml) administered by lumbar epidural injection 15 min before surgery (group A)
Study: 8460757
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with adrenaline (15 ml) administered at the end of surgery (group B)
Study: 24928286
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (DZP‐IV)
Study: 24928286
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (MDZ‐IM)
Study: 24145678
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulfate (113 patients)
Study: 17935921
Drug: Transarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial infusion (TAI) with water-in-oil-in-water (W/O/W) emulsion containing epirubicin
Study: 10898131
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg b.i.d.
Study: 2218422
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg b.i.d.
Study: 8996854
Drug: Voltaren (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren (100 mg tablets)
Study: 8875584
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline sulfate
Study: 6364906
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml normal saline solution (placebo)
Study: 25528281
Drug: CST in
Normalized name: dimethiconol (50000 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST in combination with acetylcholinesterase inhibitors (ACHEIs)
Study: 23624802
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha‐2b (PEG‐IFNα‐2b) therapy
Study: 24638207
Drug: Lozenges without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lozenges without added probiotics (control group)
Study: 3664426
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 10 mg to 20 mg twice orally
Study: 26259978
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of insulin aspart
Study: 28303726
Drug: Conventional pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pen administration of insulin aspart
Study: 18781134
Drug: Vindesine treatment
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine treatment for 2 years
Study: 12944243
Drug: Amrinone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone 1.5 mg/kg plus 10 microg/kg/min infusion for 10 hours
Study: 23461581
Drug: Intrathecal immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal immunoglobulin (1000 IU, free of preservatives) plus intramuscular immunoglobulin (3000 IU)
Study: 23461581
Drug: Intramuscular immunoglobulin
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immunoglobulin (3000 IU, with preservative)
Study: 19760991
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) Group
Study: 16572922
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg tablet formulation
Study: 10831943
Drug: Phytoestrogens (PE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (PE) 80 mg/day of isoflavones
Study: 8221449
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine mixed with DPT vaccine (combined in one injection)
Study: 8221449
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (PRP‐T and DPT vaccines)
Study: 8221449
Drug: PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T vaccine mixed with DPT vaccine
Study: 22411483
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 μg
Study: 31213063
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy targeting emotion regulation
Study: 31213063
Drug: Pre-treatment levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment levels of parent and child-reported emotion regulation
Study: 24938224
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g of milled flaxseed per day for six months)
Study: 22643948
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid drops applied with the Mygind technique for 8 weeks postoperatively
Study: 22643948
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid sprays for 8 weeks postoperatively
Study: 18640074
Drug: Flexible-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Flexible-dose pregabalin (150-600 mg/d)
Study: 18640074
Drug: Fixed-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose pregabalin (300 mg/d)
Study: 18640074
Drug: Flexible-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Flexible-dose pregabalin
Study: 18640074
Drug: Fixed-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose pregabalin
Study: 10556869
Drug: 40/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40/50 mg metrifonate
Study: 1579337
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ticlopidine b.i.d. (49 patients)
Study: 27182847
Drug: Self-management occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management occupational therapy intervention program (SMOoTh)
Study: 30305890
Drug: Goal-Directed Fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Fluid Therapy (GDFT)
Study: 23301466
Drug: Electroacupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture + medication
Study: 23301466
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture + medication
Study: 23301466
Drug: Medication (seroxat)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (seroxat)
Study: 18215590
Drug: Both Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Aspirin and Tranexamic Acid
Study: 12730088
Drug: naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (1000 mg/d)
Study: 12730088
Drug: aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (75 mg/d)
Study: 12730088
Drug: diclofenac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (150 mg/d)
Study: 1801542
Drug: deprenyl, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: deprenyl, 10 mg/day
Study: 7047649
Drug: Gentamycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin (single injection one hour before surgery)